C4 Therapeutics (CCCC) Loses -21.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Core Viewpoint - C4 Therapeutics, Inc. (CCCC) has experienced significant selling pressure, resulting in a 21.9% decline in stock price over the past four weeks, but analysts anticipate improved earnings in the near future [1] Group 1: Stock Performance and Technical Indicators - CCCC's stock is currently in oversold territory, indicated by an RSI reading of 26.06, suggesting a potential trend reversal is imminent [5] - The Relative Strength Index (RSI) is a momentum oscillator that helps identify oversold conditions when the reading falls below 30 [2][3] Group 2: Earnings Estimates and Analyst Sentiment - Analysts have raised earnings estimates for CCCC by 0.3% over the last 30 days, indicating a consensus expectation for better performance [6] - CCCC holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks, which signals a strong potential for a turnaround [7]